Jefferies cuts Evonik as Middle East disruption boost to earnings fades
Jefferies downgraded Evonik Industries to 'hold' and cut its 2027 EBITDA forecast by 9% to below €2 billion. The brokerage raised its price target to €21 and noted that share price movements may depend on potential engagement with BASF. Evonik's EBITDA is up 14% year-to-date, but Jefferies sees challenges in reaching its 2029 ROCE target.
How this was made
The 30-second read
Why it matters
The downgrade introduces new downside risk, especially ahead of the March 4, 2027 earnings release.
Market read
Analyst downgrade with revised forecasts is a fresh catalyst that can move Evonik's stock.
What to watch
Potential BASF engagement and synergies from a possible acquisition could mitigate downside.
Background
Jefferies' downgrade follows earlier speculation about a BASF takeover; the broker now sees limited upside.
Market effects
The downgrade may weigh on the broader specialty chemicals sector in Europe.
European chemical stocks could see modest weakness.
Limited to investors tracking German industrials and chemical peers.
Counterpoint
If the market overreacts, Evonik's strong Advanced Technologies segment could support a rebound.
Key entities
- companyEvonik Industries
German specialty chemicals maker.
- analystJefferies
Brokerage providing the downgrade and forecast.
